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Abstract 
Nano-sized colloidal carriers represent innovative drug delivery systems, as they allow a targeted 
and prolonged release of poorly water-soluble drugs, improving their bioavailability and modifying 
their pharmacokinetic parameters. In this work we describe cyclodextrin-based nanosponges, 
obtained through polimerization of -cyclodextrin with diphenyl carbonate as the cross-linking 
agent, loaded with a novel multi-effective heterocyclic compound, DB103, able to regulate key 
cellular events involved in the remodelling of vessels wall. Fabrication and drug-loading 
procedures, as well as physical-chemical characterization and drug-release profile of the novel 
colloidal system are reported. Results achieved demonstrate the ability of nanosponges to enclose 
efficiently the target drug and release it slowly and continuously, thus suggesting the exploitability 
of the novel system for the local therapy of vessels wall subjected to percutaneous intervention. 
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4 
 
1. Introduction 
Cardiovascular diseases (CVDs), represented by disorders of heart and blood vessels, are a major 
health problem in both developing and developed countries. Actually, besides being the main cause 
of morbidity worldwide, they represent the leading killer of men and women by 45 and 65 years of 
age, respectively, and are expected to be responsible for 23,3 million deaths by 2030 [1]. 
Most of CVDs are caused by atherosclerosis, a process of vessel wall degradation and calcification 
which leads to narrowing up to occlusion of blood vessels [2], thus requiring a percutaneous 
coronary intervention (PCI) [3]. Different techniques and devices have been developed to either 
remodel or remove the causes of acute and chronic vessel obstruction, increasing luminal cross-
sectional area and improving blood flow. However, despite improvement in equipments, limitations 
still remain. Actually, patients may experience abrupt vessel closure at the treated site, as well as 
localized thrombus and vessel dissection. Moreover, recurrence of restenosis may affect up to 60% 
of patients, within 3 to 12 months after the treatment. Drug-eluting stents (DES) revamped the field 
of interventional cardiology, allowing to reduce the rate of restenosis and the need for repeated 
vascularization. However, some concerns still remain about their safety, particularly due to the rare 
but potentially life-threatening complication of in-stent thrombosis [4-6]. Inflammatory responses, 
local toxicity and allergic reactions may emerge to enhance restenosis and thrombosis, as a 
consequence of sub-optimal polymer biocompatibility. Actually, despite the success of DES, side 
effects to polymer coating still represent the main drawback of intra-vascular devices [7].  
Accordingly, they need to be improved, and this results in an interesting field of research. In 
particular, more effective drugs should be identified, to be exploited for DES manufacturing, 
bearing in mind that the ideal therapeutic agent for vessel wall subjected to PCI should combine an 
anti-restenotic effect with a pro-healing action. Moreover, novel and more suitable drug carriers 
should be investigated as well, to promote endothelial healing through a controlled and predictable 
release of the effective drug in the targeted area avoiding any toxic side effects. 
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Pursuing our research interest in the field of CVDs treatments [8], we disclosed a novel multi-
effective compound, namely 2-(3,4-dimethoxyphenyl)-3-phenyl-4H-pyrido[1,2-a]pyrimidin-4-one 
(DB103, Chart 1), which stood up as the ideal drug candidate for DES manufacturing [9-12]. 
Actually, our compound proved to inhibit human aortic smooth muscle cells (HAoSMCs) 
proliferation, responsible for the abnormal neointimal formation leading to restenosis. Moreover, in 
these cells, DB103 inhibited also MMP-9 up-regulation and activity, which are induced by smooth 
muscle cell hyperplasia during atherosclerosis and restenosis to remodel the surrounding 
extracellular matrix [10]. In addition, it reduced the cytokine-induced expression of COX-2, 
followed by reduction of PGE2 production. On the contrary, in human umbilical vein endothelial 
cells (HUVECs), our drug candidate did not affect COX-2 protein and gene expression and did not 
modify the production of prostanoids, particularly the prostacyclin PGI2 which acts synergistically 
with nitric oxide to maintain normal vascular functions, i.e., atheroprotection, inhibition of platelet 
activation, and vascular smooth muscle contraction. Accordingly, DB103 is able to regulate 
excellently key events involved in the remodelling of vessels wall. 
Tested ex-vivo on platelet-rich plasma obtained from whole blood, DB103 proved to counteract 
platelet aggregation induced by agonists such as collagen (5 g/ml) and U46619 (1 M), both 
involved in the TxA2 pathway, showing IC50 values in the low micromolar range. It also inhibited 
platelet activation, as demonstrated by its ability to reduce the mean platelet component parameter, 
a measure of platelet density, sphering and swelling that correlates with the platelet activation state 
and can be easily determined exploiting the Advia 120 Hematology System [11]. 
Therefore, besides staking out restenosis, our compound may in principle prevents thrombotic 
events often coming on the scene of DES treatment. 
However, to be exploited as the active pharmaceutical ingredient of DES, DB103 should be 
incorporated within a suitable matrix, able to release it over time, slowly and safely. This is why we 
deepened our study, developing a promising and innovative system for drug delivery. In particular, 
we focussed on cyclodextrin-based nanosponges, obtained through polimerization of -cyclodextrin 
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with diphenyl carbonate as the cross-linking agent. This hyper-cross-linked polymer is able to 
incorporate drugs within its structure, either as inclusion complexes or as non-inclusion complexes. 
Besides preserving drug stability, -cyclodextrin nanosponges turn out to be fully bio-compatible, 
showing no cytotoxic and haemolytic activities [13]. Moreover, they can be easily sterilized, being 
thermally stable up to 300 °C. This carrier has already been exploited as a versatile drug delivery 
system [14-17], but it has never been investigated as an exploitable polymer for the controlled 
delivery of drug from DES, particularly for those equipped with reservoirs of drug carrying 
polymers [18]. Accordingly, it represents the best candidate for our study. In this work we describe 
the obtainment of the novel DB103-nanosponge system, which was fully characterized through 
physical-chemical data, and drug loading and releasing profile. 
 
2. Experimental Section 
Materials and Methods. 
-cyclodextrin, diphenylcarbonate, 2-aminopyridine, ethyl 3-(3,4-dimethoxyphenyl)-3-
oxopropanoate, N-bromosuccinimide, bis(triphenylphosphine)palladium(II) dichloride, 
phenylboronic acid, and all other chemicals were from Sigma-Aldrich (St. Louis, MO). Melting 
point of DB103 was determined using a Reichert Köfler hot-stage apparatus and it is uncorrected. 
Routine 1H-NMR spectra were recorded either in DMSO-d6 (DB103) or in D2O solution 
(nanosponge and DB103-loaded nanosponges), on a Bruker 400 spectrometer operating at 400 
MHz. Routine infrared spectra were obtained with an Agilent Cary 620 FT-IR Microscope 
Spectrometer. 
Chemical synthesis of DB103 
The target compound, 2-(3,4-dimethoxyphenyl)-3-phenyl-4H-pyrido[1,2-a]pyrimidin-4-one, 
namely DB103, was synthesized by V.C. and S.S. at the Department of Pharmacy of the University 
of Pisa, Italy, following the previously reported procedure depicted in Scheme 1 [11]. Briefly, the 
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key intermediate 2-(3,4-dimethoxyphenyl)-4H-pyrido[1,2-a]pyrimidin-4-one, 3, obtained from 2-
aminopyridine 1 and ethyl 3-(3,4-dimethoxyphenyl)-3-oxopropanoate 2 in polyphosphoric acid 
[19], was treated with N-bromosuccinimide in refluxing chloroform to afford the corresponding 3-
bromo derivative, 4, which gave the target DB103 through reaction with phenylboronic acid in the 
presence of bis(triphenylphosphine)palladium(II) dichloride and an aqueous solution of Na2CO3, in 
EtOH/toluene solution. The crude product was purified by crystallization from MeOH, than 
anhydrified in a vacuum oven and characterized through physico-chemical and spectral data. Yield: 
90%. P. f.: 182-184 °C. IR (, cm-1): 1657, 1592, 1511, 1463, 1418, 1260, 1136, 1015. 1H-NMR (, 
ppm, Hz): 8.96 (d, 1H, J= 7.08), 7.95 (t, 1H, J=8.79), 7.73 (d, 1H, J=8.79), 7.34-7.10 (m, 7H), 6.88-
6.75 (m, 2H), 3.72 (s, 3H), 3.36 (s, 3H). 
Chemical synthesis of -cyclodextrin-based nanosponges (CD-NS) 
-cyclodextrin nanosponges were synthesized following a previously reported procedure, devised 
by Trotta and co-workers [14] and depicted in Scheme 2. Briefly, a mixture of -cyclodextrin, 
anhydrified in a vacuum oven (1.00 mmol) and diphenylcarbonate (4.00 mmol) were heated under 
stirring at 90 °C for 5 h. Once the reaction was completed, the solid cross-linked nanosponge was 
ground in a mortar and washed with water, to remove the unreacted -cyclodextrin, then extracted 
with ethanol, to remove phenolic by-product and the residual diphenylcarbonate. The white product 
so obtained was anhydrified in a vacuum oven, then characterized through spectral data. IR (, cm-
1): 3316, 2927, 1773, 1648, 1229, 1153, 1026. 1H-NMR (, ppm, Hz): 4.98 (d, 1H, J= 3.68), 3.88 (t, 
1H, J= 9.49), 3.79-3.76 (m, 3H), 3.59 (dd, 1H, J= 3.60, 9.93), 3.50 (t, 1H; J= 9.0). 
Preparation of DB103-loaded nanosponges (DB103-NS) 
The loaded nanosponges were prepared at a nanosponge:compound ratio of 1:1, w/w. Accordingly, 
100.0 mg of CD-NS and 100.0 mg of DB103 were dissolved in anhydrous DMF and left under 
stirring at room temperature for 1.0 hour. Then, the solvent was evaporated under reduced pressure 
and the resulting solid was washed with water and acetone, then anhydrified in a vacuum oven and 
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characterized through spectral data. IR (, cm-1): 1658, 1627, 1593, 1512, 1463, 1417, 1324, 1234, 
1137, 1017. 1H-NMR (, ppm, Hz): 7.84 (s, 1H), 7.21 (t, 1H, J=7.45), 6.81 (t, 1H, J=7.46), 6.79 (t, 
1H, J=7.64), 4.98 (d, 1H, J=3.72), 3.86 (t, 1H, J=9.46), 3.78-3.73 (m, 3H), 3.57 (dd, 1H, J=3.66, 
J=9.94), 3.52 (t, 1H, J=9.60), 2.92 (s, 3H), 2.77 (s, 3H). 
Preparation of binary mixture of DB103 and nanosponges 
A binary physical mixture of test compound, DB103, and nanosponges was prepared by mixing, in 
a glass mortar and in a 1:1 weight ratio, appropriate amounts of the two solid components. 
UV spectral analysis of DB103 
2 mg of DB103 were dissolved in 10 mL of ethanol and the resulting solution was scanned on a 
Perkin Elmer UV-Vis Spectrophotometer Lambda 25, between 200 and 400 nm, to determine the 
wavelength of maximum absorbance of the test compound. This latter, established at 318 nm, was 
exploited in the following loading and releasing studies. 
Attenuated Total Reflectance-Fourier transform infrared spectroscopy (ATR-FTIR) 
ATR-FTIR spectra of DB103, -cyclodextrin-based nanosponge (CD-NS), their 1:1 physical 
mixture and DB103-loaded nanosponge (DB103-NS) were recorded on a FTIR Cary 620 
microscope spectrometer using a micro ATR slide accessory with a Germanium crystal, in the 
region ranging from 3500 to 950 cm-1. Chemical imaging data were collected on a 620 FTIR 
imaging system with a 64x64 Focal Plane Array (FPA) detector cooled by liquid nitrogen, utilizing 
Agilent’s ATR-Imaging technique (Figures 1-4). Experimental parameters exploited for data 
processing are shown in Table 1. 
Differential scanning calorimetry (DSC) 
The thermal behaviour of DB103 and DB103-loaded nanosponge (DB103-NS) were studied using a 
Perkin Elmer Pyris 6 DSC instrument under dry nitrogen purge. Samples were scanned at the rate of 
10 °C/min, over the 45-280 °C temperature range. The instrument was calibrated with an indium 
sample (99.99% pure), having a melting point of 156.6 °C and a melting enthalpy of 28.4 J/g. The 
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Pyris Manager software was used to extrapolate onset value temperatures and melting enthalpy for 
each thermal event. Thermograms obtained are reported in Figure 7. 
Raman spettroscopy 
The Raman spectra of DB103 and DB103-loaded nanosponge (DB103-NS) were recorded with a 
confocal Labram instrument (Jobin Yvon Horiba) equipped with a He-Ne laser at 632.8 nm and a 
CCD detector (254x1024), cooled by Peltier effect. Spectra were recorded in backscattering after 
focalisation in several positions within a small area of the sample (ca. 100 m x 100 m). The 
maximum laser power employed was 5 mW and the recording time for good signal-to-noise ratio 
was 100-200 s. GRAMS/AI 7.02 was used for the elaboration of the spectra, which are reported in 
Figure 8. 
Loading efficiency and loading capacity 
The loading efficiency and capacity of the DB103-NS system was determined 
spectrophotometrically on 2 mg of powder, accurately weighted, which was suspended in 10 mL of 
ethanol and sonicated for 10 minutes, to break the loaded nanosponge. The resulting solution was 
filtered, then suitably diluted and analysed by UV at 318 nm. Experiments were performed in 
triplicate and the loading efficiency and capacity were calculated by the following formulae (1) and 
(2),20 respectively, converting the observed absorbance into mass (g) by the use of a suitable 
calibration curve: 
Loading Efficiency = (Effective Drug Content/Theoretical Drug Content) x 100   (1) 
Loading Capacity = (Effective Drug Content/DB103-NS System Mass) x 100   (2) 
In vitro releasing studies 
Drug releasing from DB103-loaded nanosponge (DB103-NS) was monitored by UV spectroscopy. 
The loaded carrier, 2 mg, was placed in a 10.0 mL dissolution vessel and kept under stirring, at 
37°C, in PBS solution. At selected time-points, 1.00 mL of solution was removed from the flask 
and replaced with 1.00 mL of fresh PBS, to maintain sink conditions. Collected samples were 
analysed by using Perkin Elmer UV-Vis Spectrophotometer Lambda 25. Selected time-points were: 
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0 min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 24 h and 48 h. The absorbance observed at 318 nm was 
converted into mass (μg) by using a suitable calibration curve. Blank measures (PBS) were used as 
the negative controls. Experiments were performed in triplicate and cumulative percentage of drug 
eluted with time, expressed as means±SEM, are reported in Figure 9. 
 
3. Results and Discussion 
Nanosponges are a new type of fully biocompatible cross-linked polymer endowed with great 
encapsulation ability and high solubilization capacity with regard to different types of molecules 
[13,14,20-30]. As their production is flexible and cost-effective, they represent a useful and 
innovative tool whose employment in drug delivery should be increased. In this study, we 
investigate the use of nanosponges for the obtainment of a novel system enclosing the multi-
effective heterocyclic compound DB103, able to regulate key cellular events involved in the 
remodelling of vessels wall. 
Firstly, following the previously reported procedure of Trotta and co-workers [14], we synthesized 
the carrier from -cyclodextrin and diphenylcarbonate, obtaining a white pure matrix, consisting of 
a spherical shape nanoparticle population characterized by a narrow sizes distribution (data not 
shown). Once characterized through spectral data (Figures 2 and 5), nanosponges were then 
exploited to prepare the novel BD103-NS system, characterized in turn (Figures 4 and 6). Both 
nanosponges and BD103-NS system can be easily dispersed in water, giving rise to opalescent and 
stable colloidal suspensions [14]. Avoiding a gradient of concentration in the volume and 
guaranteeing equal excitation of the nuclei within the spectral range, these nano-sized systems may 
be easily analyzed through 1H-NMR data without using magic angle spinning conditions. The size 
of the particles are small enough to allow their incoherent isotropic tumbling motions, and both 
dipolar coupling and chemical shift anisotropy can be eliminated. Moreover, brownian motions help 
to sharpen the signal of the colloidal particles and of the adsorbed compound [31-33]. 
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Once loaded with the active compound, nanosponges changed their 1H-NMR spectrum, as can be 
easily deduced comparing Figures 5 and 6. Chemical shifts pertaining to protons H-1 (=4.98), H-2 
(=3.56), and H-6 (=3.79) of the carrier, protruding outside the cavity, were almost unaffected by 
complexation but those related to protons H-3 and H-5, located inside the carrier cavity, showed an 
upfield shifting ranging from 0.019 to 0.035 ppm, thus confirming an inclusion complexation 
between nanosponges and the guest drug. Proton H-4 (=3.50 in the unloaded carrier) was affected 
too, and the 0.02 ppm downfield shifting observed in the loaded nanosponges corroborates the tight 
interaction between the carrier and DB103. Regarding this latter, the 1H-NMR spectrum was 
significantly biased upon loading on nanosponges. Indeed, in the DB103-NS system, both the 
aromatic protons and the alkyl protons of the dimethoxy substituents were shifted upfield by 0.50 to 
1.12 ppm. 
The novel BD103-NS system was then studied in depth, to ascertain its physicochemical 
characteristics and investigate both the loading efficiency/capacity and the ability to release the 
loaded drug. 
ATR-FTIR Studies. Infrared spectroscopy was used to estimate interactions between nanosponge 
and the guest molecule in the solid state. Spectra of both the BD103-NS system and of the single 
components, as well as of the binary physical mixture of DB103 and NS, were registered exploiting 
the ATR-FTIR, a profitable technique allowing high resolution images, short times data collections, 
high spatial resolution with high signal-to-noise ratio, and full information about the entire sample 
[34]. Thanks to the use of a Focal Plane Array Detector (FPA), which works as a camera, it is 
possible to collect simultaneously spectra from each single pixel of the image, giving a univocal IR 
per point, analyzing an area of 1.1 µm2.  
Figure 1 shows the ATR-FTIR spectrum and the visible and FPA images (2D and 3D in false 
colors) of DB103. Distinctive bands of DB103 were found at 1657 cm-1, due to C=O stretching, 
1511 cm-1, due to C=N stretching of aromatic ring, 1463 cm-1, due to CH3 bending vibration, 1260 
cm-1, due to the asymmetric stretching of C-O-C, and 1015 cm-1, due to the symmetric stretching of 
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C-O-C. ATR-FTIR spectrum of plain cyclodextrin-nanosponges, reported in Figure 2, showed 
typical bands at 3316 cm-1, due to O-H stretching, 2927 cm-1, due to C-H stretching vibration, 1773 
cm-1, due to the presence of the carbonyl cross-linker, and 1026 cm-1, due to C-O stretching of 
primary alcohol, thus proving to match fully IR data described by the literature for this nanocarrier 
[20]. 
The binary physical mixture DB103-nanosponge, analyzed by ATR-FTIR, provided the spectrum 
reported in Figure 3, which turned out to be the mere superimposition of the spectra registered for 
the single components, DB103 and NS. Indeed, neither shifts nor modifications of the absorption 
bands were observed, thus demonstrating the absence of significant interactions between the 
nanosponge and the drug composing the mixture. 
On the contrary, significant shifts of distinctive bands to higher frequencies were observed in the 
ATR-FTIR spectrum of the DB103-NS system, depicted in Figure 4, as a result of complexation 
between the nanosponge and the guest drug. The main stretching due to the C=O bond of DB103 
turned out to be shifted, from 1657 cm-1 to 1688 cm-1. The same was also true for the asymmetric 
stretching of C-O-C, from 1260 cm-1 to 1272 cm-1. Moreover, bands at 3292 cm-1 and 2979 cm-1, 
due to O-H and C-H stretching vibration of nanosponges, respectively, changed their shape and 
their intensity. Finally, stretching at 1026 cm-1, due to C-O of primary alcohol, shifted to 1037 cm-1 
in the solid system. 
DSC Studies. Figure 7 represents the DSC thermograms of DB103 and DB103-NS system. The 
thermogram of the pure heterocyclic compound exhibited mainly a double endotherm peak, at 165 
and 175 °C respectively, accompanied by a small and broad peak at 100 °C due to water traces. On 
the contrary, when the compound is complexed with the nanosponge, we assist to a substantial 
reduction in the endotherm peak intensity and a shift to lower temperatures: the double distinctive 
peak of DB103 has been replaced by a single broad event, at 164 °C. Moreover, the thermogram of 
the DB103-NS system displayed an additional broad peak, at 79 °C. Both the events confirm the 
occurrence of a complex phenomenon between the two components. 
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Raman Spectroscopy Studies. As Raman spectroscopy is a key technique for studying interactions 
between drugs and polymers, we registered and compared Raman spectra of DB103 and DB103-NS 
system. Results obtained are showed in Figure 8. Key peaks of DB103, highlighted in the upper 
spectrum, turned out to be either splitted or displaced in the spectrum of DB103-NS system. 
Actually, in this latter, additional peaks at 1600, 1330, and 650 cm-1, due to the vibrational 
absorptions of the heterocyclic ring, are clearly visible, thus demonstrating that a close complex has 
been formed between the pyridopyrimidinone core and the network of -cyclodextrins. 
Drug loading efficiency and drug loading capacity. The amount of DB103 loaded on the 
nanosponge was determined spectrophotometrically on a fixed amount of powder. Exploiting a 
suitable calibration curve, and using the previously mentioned formulae, the calculated percent of 
drug loading efficiency turned out to be 95±16 while the drug loading capacity resulted 35.6±8. It is 
known that the degree of cross-linking chosen in the manufacturing of nanosponges affects the 
complexation capacity of the carrier, as it modulates the size of the tridimensional network hosting 
the drug [35]. The 1:4 molar ratio between -cyclodextrin and diphenylcarbonate pursued in our 
study guarantees a profitable interaction of DB103 with the cavities of the nanosponge, as the 
percent of both drug loading efficiency and capacity resulted highly favorable. 
Drug releasing profile. The releasing profile of DB103 from the DB103-NS system was 
investigated in PBS solution and evaluated at specified time intervals, covering a time-span of 48 
hours. Results obtained, reported as the cumulative percentage of drug released as a function of 
time, are plotted in Figure 9. DB103 is released slowly and steadily, as less than 50% drug release 
was achieved over 48 hours of observation. The in vitro release profile was biphasic. A limited 
initial burst release, due to surface associated drug and represented by less than 10% loaded drug up 
to 0.5 hour, is then followed by a slow and sustained release phase, in which the entrapped drug 
slowly diffused into the release medium. The observed releasing profile confirms the good 
complexation and the strong interaction between the drug and the nanosponge network. 
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Since the DB103-NS system has been designed for the controlled delivery of drug from DES, the 
observed releasing profile turns out to be particularly convenient, as it allows a constant therapeutic 
effect minimizing potential toxicities. 
 
4. Conclusions 
Manufacturing of DES represents a challenging field of research. Despite their widespread use in 
interventional cardiology, these devices still presents some drawbacks, pertaining to both the drug 
and the carrier exploited in their fabrication. Actually, while the former should limit the growth of 
excess neointimal hyperplasia without preventing ultimate re-endothelialization of the stented 
artery, the latter should promote endothelial healing through a controlled release of the drug, 
avoiding any toxic side effects. In this work we presented a novel prototype candidate for DES 
manufacturing, obtained by combining a multi-effective compound, DB103 [9], with an innovative 
carrier, represented by cross-linked, -cyclodextrin-based nanosponges. 
Although already exploited to increase drug solubility and bioavailability [36], the colloidal 
nanocarrier here proposed has never been proposed for DES manufacturing, particularly those 
equipped with reservoirs of drug carrying polymers [18]. 
However, being fully bio-compatible and devoid of any cytotoxic and haemolytic activities [13], -
cyclodextrin-based nanosponges may represent the ideal support to exploit in cutting-edge DES, as 
they allow to overcome in principle side effects arising from the coating polymer currently used [7]. 
The novel DB103-NS system was characterized through physico-chemical data, which 
demonstrated a clear and high grade inclusion of the active compound within the network of the 
nanosponge. In vitro release studies revealed the ability of the system to retain and release the 
active compound slowly and gradually, without any significant initial burst effect, thus assuring in 
principle an enduring therapeutic action at the site of intervention. Accordingly, the DB103-NS 
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system here described represent an innovative and reliable prototype of formulation exploitable for 
the local therapy of vessels wall subjected to percutaneous intervention. 
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Figure 1. ATR-FTIR spectrum, visible and FPA images (2D and 3D in false colors) of DB103 
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Figure 2. ATR-FTIR spectrum, visible and FPA images (2D and 3D in false colors) of 
nanosponges. 
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Figure 3. ATR-FTIR spectrum, visible and FPA images (2D and 3D in false colors) of the binary 
physical mixture of DB103 and nanosponges. 
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Figure 4. ATR-FTIR spectrum, visible and FPA images (2D and 3D in false colors) of DB103-NS 
system. 
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Figure 5. 1H-NMR Spectrum of -Cyclodextrin-based Nanosponges, recorded in D2O. 
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Figure 6. 1H-NMR Spectrum of DB103-NS System, recorded in D2O. 
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Figure 7. DSC Thermograms of DB103 (black line) and DB103-NS System (red line). 
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Figure 8. Raman Spectra of DB103 and DB103-NS System. 
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Figure 9. In Vitro Drug Releasing Profile of DB103-NS System. 
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Scheme 1. Chemical Synthesis of DB103. 
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Scheme 2. Chemical Synthesis of -Cyclodextrin-based Nanosponges 
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Table 1. Experimental Parameters of ATR-FTIR Study. 
 
Parameter Value  
Number of background scans 256 
Number of sample scans 256 
Spectral resolution (cm-1) 8 
Speed (KHz/sec) 2.5 
Aperture (cm-1) 4 
Post processing Principal component analysis (PCA) CO2 and H2O subtraction 
 
 
 
